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Table 1
Daily Micafungin Antifungal Prophylaxis Results
Observations Number (%) or Median (Range)
Total patients 28
Duration (days) 37 (3-94)
Average dose - start (mg/kg/day) 2.1 (0.8-4.3)
AST
Baseline elevation 7 (25)
End elevation 7 (25)
Increase  2x baseline 17 (61)
ALT
Baseline elevation 11 (39)
End elevation 10 (36)
Increase  2x baseline 19 (68)
Total Bilirubin
Baseline elevation 0
End elevation 4 (14)
Increase  2x baseline 24 (86)
Creatinine
Baseline elevation 1 (4)
End elevation 1 (4)
Increase  2x baseline 10 (36)
Table 1
Alternate day Micafungin Antifungal Prophylaxis: Results
Observations Number or Median (Range)
Total number of patients 33
Total weeks of alternate day
Micafungin
10 (4-28)
Liver proﬁle trends during
Micafungin prophylaxis
Baseline ALT 49 (15-164)
Baseline AST 51 (15-1080)
Baseline direct bilirubin 0.1 (0-4.3)
Highest ALT 138 (26-491)
Highest AST 105 (37-900)
Highest direct bilirubin 0.2 (0-9)
End of therapy ALT 98 (20-190)
End of therapy AST 52 (18-156)
End of therapy direct bilirubin 0.1 (0.1-8.9)
Breakthrough fungal infection 2
Patient 1 Candida albicans fungal esophagitis -
conﬁrmed by culture
Patient 2 Line infection - culture positive for
Candida glabrata
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Background: Disseminated fungal infection is a major cause
of morbidity and mortality in children undergoing HCT.
Prophylaxis with amphotericin B can be limited by renal
toxicity. Oral triazoles can be limited by poor absorption,
large interindividual pharmacokinetic (PK) variability, and
hepatic toxicity, leading to interruptions in therapy and
breakthrough infections. Micafungin has potential advan-
tages, due to its better safety proﬁle, speciﬁcally in terms of
hepatic and renal toxicity, and lack of drug-drug interactions
with common medications used in the HCT setting.
Both animal and adult human data suggest that alternate
day dosing schedule can be effective. In a PK study in pedi-
atric HCT patients, we have previously shown detectable and
protective Micafungin levels at 48 hours after the dose
(Mehta et al, 2010). Here we report our clinical experience of
use of alternate day micafungin (3 mg/kg) in high risk
pediatric patients undergoing HCT.
Methods: A total of 33 infants and children with various
hematological and immune deﬁciency disorders undergoing
HCT were reviewed retrospectively. The median age was 5
years (range 0.5-20). None of the patients had a history of
prior fungal infection.
Results: Results are described in Table 1. Eleven patients
were started on alternate day Micafungin after sustaining
liver dysfunction from voriconazole, liver graft vs. host
disease (GVHD), disseminated viral infection and/or veno-
occlusive disease. Three patients developed liver
dysfunction while on alternate day micafungin from similar
causes. In all these patients, continuation of micafungin did
not worsen liver dysfunction, which in fact improved in
most patients over time. Two patients developedbreakthrough fungal infection during alternate day
micafungin prophylaxis. One patient had been on
micafungin for 8 weeks and another for 14 weeks at the
time of developing breakthrough candida line infection and
esophagitis respectively. Of note, both these patients had
refractory liver and gastrointestinal GVHD and were
signiﬁcantly immunocompromised from multiple immune
suppressive therapies for their GVHD.
Conclusion: We conclude that, alternate day micafungin
prophylaxis is safe and well tolerated; speciﬁcally even in
patients with baseline liver dysfunction, without additional
liver toxicity. This provides a simple prophylaxis regimen
that can be administered for prolonged duration to patients
undergoing HCT even on an outpatient basis.297
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Introduction: Historically, diagnosis of enigmatic pulmo-
nary disease after hematopoietic cell transplant (HCT) has
required lung biopsy. Recent improvements in laboratory
diagnostics and therapies for fungal infections have led to
changes in how clinicians approach pulmonary abnormali-
ties. We examined temporal trends in the use of lung biopsy
after HCT.
Methods: We retrospectively reviewed patients who
underwent their ﬁrst allogeneic HCT at the Fred Hutchinson
Cancer Research Center between the years 1993-1997 and
2003-2007. Data on lung biopsies were abstracted from
a prospectively collected database of all recipients from these
two cohorts (NEJM 2010). Outcome datawere analyzed using
Fisher's exact test. Hazards for lung biopsy for the two
cohorts were determined using a Cox-proportional hazards
model with death and relapse considered competing risks.
Results: A total of 50/1418 (3.5%) patients underwent 52
post-HCT surgical lung biopsies during 1993-1997 compared
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2007 cohort. The median time to biopsy post-HCT was 72
days (IQR 32-89) for the early cohort and 97 days (IQR 33-
119) for the more recent cohort, for an overall biopsy inci-
dence of 0.052 and 0.02 per 1000 patient days, respectively.
Patients in the 2003-2007 cohort were less likely to undergo
a lung biopsy (HR 0.52, CI 0.28-0.98, P¼ .04) when compared
to patients in the 1993-1997 cohort. Although a similar
number of patients underwent a bronchoscopy between the
two cohorts (272/1418 [19.2%] vs. 243/1148 [21.1%], P ¼ .22),
more patients in the early cohort underwent lung biopsy
without antecedent bronchoscopy (26/52 [50%] vs. 18/21
[86%], P ¼ .007). Infections were a more common ﬁnding at
biopsy in the early cohort (35/1418 vs. 8/1148, P < .001), but
the number of biopsies demonstrating non-infectious lesions
was similar between the two cohorts (17/1418 vs. 13/1148, P
¼ .85). Fungal infections were the major infectious etiology
in both cohorts (30/35[85%] vs. 5/8 [63%], P ¼ .15), but there
was a signiﬁcant reduction in the number of Aspergillus
species found at biopsy between the cohorts (29/52 vs. 1/21,
P < .001). A similar number of patients underwent biopsy
with a therapeutic intent in the two cohorts (8/52 [15%] vs. 3/
21 [14%]); all of those who underwent therapeutic biopsy in
the 2003-2007 cohort had documented Mucorales species.
Conclusions: Surgical evaluation of lung disease in HCT
recipients signiﬁcantly declined over a decade between
1993-1997 and 2003-2007. This decreased incidence of lung
biopsies between these two cohorts was related to a reduc-
tion in the number of biopsies for post-transplant infections,
particularly for those due to aspergillosis. We speculate that
this decline is related to the introduction of galactomannan
testing and the increased use of empiric therapy with
extended-spectrum azoles.298
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Background: The BoneMarrow Transplant Unit of Cincinnati
Children's Hospital Medical Center is a crucial care and
stressful unit. The nurses not only care for complex patients
with an array of co-morbidities, but also therapeutically
support the family. This may lead to an increased workload
and increased stress levels on nurses, which can potentially
cause burnout and turnover. Resiliency training has been
shown to decrease stress levels and improve positive outlook
in stressful work environments (Pipe et al. 2012; Steinhart et
al. 2008; Burton et al. 2010; Sood et al. 2011). There is a gap in
the literature regarding speciﬁc interventions to help new
nurses cope with the stressors of a critical care environment.
Research Question Do newly hired nurses who receive
resiliency training in addition to standard orientation
improve nurse job satisfaction scores and decrease job
turnover? Purpose/Intervention The purpose of this project
is to improve the well-being and job satisfaction of the new
staff nurses on the Bone Marrow Transplant Unit at CCHMC.
Using principles founded in positive psychology, an educa-
tion program will be implemented into the orientation
schedule of newly hired nurses. Job satisfaction scores and
stress levels will be monitored before the educational
program and at 6 months and 1 year post. Data will be
collected to determine the efﬁcacy of the additional educa-
tion throughout the orientation period.299
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Background: The purpose of our study was to evaluate the
incidence and outcome of Invasive Fungal Infections (IFI)
among patients who underwent autologous or allogeneic
Hematopoietic Stem Cell Transplantation (HSCT) at our BMT-
Unit.
Methods: This cohort-retrospective study,conducted during
02/1994 to 09/2012, involved HSCT patients admitted to our
BMT-Unit, who developed IFI.The IFI were classiﬁed accord-
ing to the modiﬁed EORTC/MSG criteria.
Results: Among 369 patients who underwent HSCT(88
allogeneic HSCT recipients and 281 autologous HSCT recipi-
ents), IFI occurred in 38 patients (overall incidence 10,3 %). 34
episodes (9,2 % of all patients) were due to molds, and 4 (1 %)
were due to yeasts. 27 episodes (30,6 %) occurred among the
allogeneic HSCT recipients, and 11 (3,9%) occurred among the
autologous HSCT recipients (RR 7.83, 95%CI 3.92-16.21).
Etiological agents were Aspergillus (31 episodes), Candida
(3 episodes), Rhodotorula (1 episode), Fusarium (1 episode),
Scedosporium (1 episode), Zygomycosis (1 episode). The
incidence of Aspergillosis was 25 % and 3,2 % among allo-
geneic and autologous HSCT recipients respectively (RR 7.80,
95%CI 3.58-17.75). The incidence of Candidiasis was 2,2 % and
0,3% among allogeneic and autologous HSCT recipients
respectively (RR 6.38, 95% CI 0.45-177.57). The overall
mortality rate for IFI was 5,7% among allogeneic HSCT
recipients and 1 % among autologous recipients (RR 5.32,95%
CI 1.13-27.79), whereas the attributable mortality rate for IFI
registered in our population was 21% (18,5 % for allogeneic
HSCT recipients and 27,2 % for autologous HSCT recipients
(RR 0.67,95% CI 0.16-3.34). The attributable mortality rate for
aspergillosis was 22,6 % (18,2 % and 33,3 % for allogeneic and
autologous HSCT recipients, respectively, RR 0.54,95%CI 0.12-
2.81), and the rate for Candida IFI was 0 %.
Conclusions: IFI represents a common complication for
allogeneic HSCT recipients.Aspergillosis is the most
frequently detected IFI in these patients. Conversely, autol-
ogous HSCT recipients rarely develop aspergillosis. Candi-
demiawas observed less often than aspergillosis among both
allogeneic and autologous HSCT recipients.
300
A Single Daily Ultra Low-Dose of Oral Acyclovir Is
Sufﬁcient to Prevent the Occurrence of Herpes Zoster
Post Hematopoietic Stem Cell Transplantation: Interim
Results of a Prospective Randomized Trial
David Dennison 1, Iman Maktoom Al Manthari 2,
Murtadha Al-Khabori 1, Revathi Raj 3, Sharat Damodar 4,
Alok Srivastava 5, Khalil Al Farsi 1, Mohammed Al Huneini 1,
Abdulhakeem Rawas 6, Yusra Al Habsi 2, Arwa Z. Al Riyami 1,
Aqeela Al Lawati 7, Intisar Al Riyami 7, Abdulla Balkhair 8,
Zahra Al Harthy 2, Shyam Sundar Ganguly 9, Salam Al Kindi 1.
1Hematology, Sultan Qaboos University Hospital, Muscat,
Oman; 2Nursing, Sultan Qaboos University Hospital, Muscat,
Oman; 3 Pediatric Hematology, Apollo Hopsitals, Chennai,
Chennai, Tamilnadu, India; 4 Hematology, Narayana
Hrudayalaya Hospital, Bangalore, India; 5 Department of
Haematology, Christian Medical College, Vellore, India;
